Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Reprod Immunol. 2012 May;67(5):413-20. doi: 10.1111/j.1600-0897.2011.01086.x. Epub 2011 Nov 1.

Effect on the production of soluble endoglin from human choriocarcinoma cells by preeclampsia sera.

Author information

  • 1Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.

Abstract

PROBLEM:

The soluble endoglin (sEng) is an antiangiogenic protein that may inhibit TGF-β1 signaling and endothelial nitric oxide synthase activation in endothelial cells. The levels of sEng increased in sera obtained from preeclampsia. The factors that increase the sEng in preeclampsia have not been known well. To investigate the factors that may increase sEng in preeclampsia, we examined the effect of preeclampsia sera on the production of sEng from human choriocarcinoma (JEG-3) cells.

METHODS:

Serum samples were taken from women with normal pregnancy and from those with preeclampsia. JEG-3 cells were cultured with serum for 24 hrs, and the sEng levels in supernatants and expression of sEng and Hemo oxygenase-1 (HO-1) mRNA in cells were measured.

RESULTS:

The addition of preeclampsia sera into JEG-3 cells led to increased release of sEng and expression of Eng mRNA. Preeclampsia sera inhibited the expression of HO-1 mRNA in JEG-3 cells.

CONCLUSION:

The results suggest that preeclampsia sera may increase the protein production of sEng and mRNA expression of Eng from JEG-3 cells like trophoblast without hypoxia and that in addition to hypoxia, preeclampsia sera may play a role of high level of serum sEng in preeclampsia patients. Decreased HO-1 activity may relate to increased sEng release.

© 2011 John Wiley & Sons A/S.

PMID:
22040284
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk